Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-01-03 @ 6:58 PM
Study NCT ID:
NCT01076751
Status:
TERMINATED
Last Update Posted:
2011-02-14
First Post:
2010-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Sponsor:
Sanofi
Organization:
Study Overview
Official Title:
Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen
Status:
TERMINATED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
delay in recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PORTREAT
Brief Summary:
Primary Objective:
* Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression
Secondary Objective:
* Describe treatment patterns
* Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others
* Describe economic and patient-reported outcomes
* Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression
Secondary Objective:
* Describe treatment patterns
* Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others
* Describe economic and patient-reported outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: